Carbamoyl-phosphate synthetase 1 deficiency: A Patient Guide

Carbamoyl-phosphate synthetase 1 (CPS1) deficiency is a rare genetic condition that fundamentally changes how the body processes the food we eat. In a healthy body, the normal breakdown of protein produces nitrogen in the form of ammonia, which is toxic to the body. The liver uses a series of enzymes known as the urea cycle to convert this ammonia into urea, which is safely excreted in urine. In children with CPS1 deficiency, the very first “gatekeeper” enzyme in this cycle is either missing or malfunctioning. Because this essential step is blocked, the body cannot clear the ammonia, and it rapidly accumulates in the blood and crosses into the brain ^[1][2].

The way the condition behaves often depends on how much enzyme activity is present. For many, it appears as a sudden, severe crisis in the first days of life as the newborn begins to digest protein for the first time. For others with a partial deficiency, the condition may remain hidden for months or years, only surfacing when the body is under extreme stress—such as during a common viral illness, a high-protein meal, or surgery. Regardless of when it appears, a confirmed high elevation in ammonia—especially when accompanied by symptoms like lethargy or vomiting—is a medical emergency that requires immediate intervention to protect the brain from injury ^[3][4].

Living with CPS1 deficiency requires a dedicated, lifelong commitment to metabolic balance. Daily management centers on a carefully restricted daily allowance of natural protein paired with specialized metabolic formulas that provide essential nutrients without overwhelming the urea cycle. This is supplemented by “scavenging” medications that provide an alternative exit route for nitrogen. Because the body’s needs change as a child grows, families work in close partnership with metabolic specialists to constantly fine-tune this balance through regular blood monitoring and nutritional adjustments ^[5][6].

While medical and dietary management can provide stability, many families and doctors eventually consider liver transplantation. Because the CPS1 enzyme is primarily located in the liver, a transplant can replace the hepatic metabolic defect, drastically reducing the risk of future ammonia crises. Though it is a significant procedure that replaces one medical regimen with lifelong immunosuppression, it represents a path toward greater metabolic stability. Throughout this journey, the goal remains the same: to manage the condition proactively so that every child has the best possible opportunity for healthy growth and development ^[7][8].